Aegerion Pharmaceuticals (AEGR) Estimates, PT Slashed at BofA/Merrill Lynch; 'Buy' Maintained
Tweet Send to a Friend
BofA/Merrill Lynch analyst Steve Byrne lowered his price target on Aegerion Pharmaceuticals (NASDAQ: AEGR) to $48.00 (from $83.00) citing uncertain ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
